OTC:AGTX
Agentix Corp.
A biotechnology firm leveraging R&D investments and discontinued operation gains to navigate a period of significant financial restructuring and operational scaling.
Key Metrics
Investment Thesis
Bull Case
AGTX presents a turnaround opportunity with massive non-cash profits from discontinued operations that could be reinvested into a revitalized product pipeline. The absence of cost of goods sold and low operating leverage suggests high margin potential once commercialization efforts yield revenue, making it an attractive speculative play for deep-value biotech investors.
Bear Case
The stock is dangerously overextended with negative shareholders' equity of $3.1M and zero current revenue to service its mounting interest obligations. Investors should avoid this ticker due to the lack of organic profitability, relying instead on non-recurring discontinued operation gains that do not indicate a sustainable core business model.
About Agentix Corp.
Agentix Corp. (AGTX) is a biotechnology-focused entity operating with significant research and development investments, primarily targeting markets requiring advanced therapeutic solutions. The company reports substantial non-cash adjustments related to discontinued operations, indicating a strategic pivot or asset restructuring within its core business units. With current assets heavily weighted in cash and prepaid expenses, the firm maintains liquidity while managing high interest expenses typical of capital-intensive pharmaceutical development.
Analysis
Management Discussion
Despite recording a non-cash profit of $567k primarily driven by discontinued operations, the company's operational cash flow turned sharply negative at -$125k, eroding its cash balance from $6.5M to $4.4M. Management appears to be leveraging asset sales or restructuring gains to offset substantial operating losses and interest expenses, though the lack of organic revenue growth remains a critical concern for sustainability.
Industry Overview
The biotechnology sector is characterized by high failure rates in clinical trials and significant upfront capital requirements for R&D before any commercial revenue materializes. Companies like AGTX often operate with negative operating profits during early-stage development, relying on strategic partnerships or asset sales to maintain liquidity while building their pipeline.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $1.4M | $744.8K | $513.3K |
| Operating Income | $-1.4M | $-744.8K | $-513.3K |
| R&D | $711.5K | $175.3K | $181.0K |
| G&A | $140.0K | $346.5K | $69.9K |
| Other OpEx | $520.2K | $223.0K | $262.4K |
| Non-Operating Income | $-2.0K | $159.7K | $-53.8K |
| Interest Expense | — | $21.0K | $42.7K |
| Interest Income | — | $248 | $0 |
| Pre-Tax Income | $-1.4M | $-585.2K | $-567.0K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-1.4M | $-585.2K | $-567.0K |
| Discontinued Ops | $0 | $0 | $1.1M |
| Net Income | $-1.4M | $-585.2K | $567.0K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-1.4M | $-585.2K | $567.0K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $261.4K | $106.4K | $100.3K |
| Cash & Equivalents | $12.4K | — | — |
| Prepaid Expenses | $249.0K | $99.8K | $95.8K |
| Other Current Assets | $0 | $6.5K | $4.5K |
| Long-Term Assets | $0 | $0 | $0 |
| Total Assets | $261.4K | $106.4K | $100.3K |
| Current Liabilities | $2.5M | $2.7M | $3.2M |
| Accounts Payable | $1.1M | $961.7K | $968.9K |
| Other Current Liab | $1.4M | $1.7M | $2.2M |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $2.5M | $2.7M | $3.2M |
| Shareholders' Equity | $-2.2M | $-2.6M | $-3.1M |
| Paid-In Capital | $3.0M | $3.3M | $3.3M |
| Retained Earnings | $-5.4M | $-6.0M | $-6.5M |
| AOCI | — | $12.4K | $35.4K |
| Total L&E | $261.4K | $106.4K | $100.3K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-1.4M | $-585.2K | $567.0K |
| Non-Cash Adjustments | $138.8K | $294.1K | $-1.1M |
| Working Capital Changes | $1.1M | $180.6K | $433.9K |
| Cash from Operations | $-88.5K | $-110.4K | $-125.1K |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $100.0K | $93.0K | $100.0K |
| FX Effect | $765 | $11.6K | $23.0K |
| Net Change in Cash | $12.2K | $-5.8K | $-2.1K |
| Beginning Cash | $145 | $12.4K | $6.5K |
| Ending Cash | $12.4K | $6.5K | $4.5K |
Frequently Asked Questions
How does Agentix Corp. make money?
1) Research and Development focused on novel therapeutic discovery with annual spend exceeding $180k; 2) Discontinued Operations generating non-cash profits of approximately $1.1M likely from asset sales or spin-offs; 3) Corporate Headquarters managing general administrative functions and interest obligations on existing capital structures.
What are the main risks for AGTX?
1) Severe liquidity pressure with a net profit deficit and accumulated retained earnings loss of over $6.5M; 2) High interest expense burden relative to current cash reserves, risking solvency if financing dries up; 3) Lack of recurring revenue streams as total revenue remains at zero across recent reporting periods; 4) Volatile cash flow from operations turning negative while working capital changes fluctuate drastically.
What is AGTX's competitive advantage?
1) Significant accumulated R&D pipeline potential despite current revenue constraints; 2) Strategic access to financing evidenced by recent $100k cash inflows from equity or debt issuances; 3) Operational flexibility derived from minimal long-term liability exposure and zero cost of goods sold structure.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.